Significant Drug-Drug Interaction Between Dolutegravir and Isoniazid-Rifapentine
Polly Clayden, HIV i-Base; Posted Feb 22, 1:40 p.m. ET
Dolutegravir (Tivicay) given with once-weekly isoniazid-rifapentine led to marked cytokine release and serious adverse events in a drug-drug interaction study.
Heather Boerner, TheBody; Posted Feb 22, 10:14 a.m. ET
Science guided Switzerland away from prosecuting people living with HIV for theoretically exposing their partners to the virus. Could it happen here, too?
'U=U': What's It All About?
Camille Arkell, Canadian AIDS Treatment Information Exchange; Posted Feb 21, 12:28 p.m. ET
When a person taking antiretroviral treatment has an ongoing undetectable viral load and is engaged in care, they do not transmit HIV to their sexual partners. Here is why supporting "undetectable equals untransmittable" is important.
PHAT Life: Effective HIV Intervention for Youth in the Criminal Justice System
National Institues of Health; Posted Feb 21, 11:17 a.m. ET
A group risk-reduction intervention to promote knowledge about HIV/AIDS, positive coping, and problem-solving skills for high-risk teens in the juvenile justice system showed great potential for reducing sexual risk-taking.
Everyone living with HIV has a story to tell. Find out how to share your own experiences in one or both of the series below, which feature the writings of readers like you.
Regardless of where or how it happened, the day you received your HIV-positive diagnosis was likely among the most intense days you'll ever live through. Some of TheBody.com's readers have generously shared their experiences -- to reflect on how they've changed, and so that others would know that they too can survive, and even thrive, following that fateful day. How did you get through it?
Many types of medications can save or improve lives, but they can also have unintended consequences. For some people living with HIV, taking meds can be a complicated cycle -- and for others, a Sunday stroll. Medication side effects can be mild or life altering, horrible or even pleasurable; some people living with HIV never experience any at all. It seems like everyone's got a story about side effects. What's yours?
Struggling With Crystal Meth? There Are Research Studies Out There for You
Gabriel Torres, TheBody; Posted Feb 21, 9:40 a.m. ET
A multi-site trial will explore whether medicine can make recovery easier, while a New York-based trial will see how meth affects cognitive function in HIV-positive men.
Will De-Simplification of HIV Treatment Become Common in High-Income Countries?
Sean R. Hosein, Canadian AIDS Treatment Information Exchange; Posted Feb 20, 2:34 p.m. ET
As more people start HIV treatment, researchers are exploring ways to cut costs. Single tablets can be replaced by a few pills comprising cheaper generic drugs.
What to Expect After Bottom Surgery: One Transgender Woman's Experience With Vaginoplasty
JD Davids, TheBody; Posted Feb 20, 2:11 p.m. ET
"After you finish with surgery, the journey begins of actually relearning yourself," Nyala Moon says. "Because once you get the surgery ... you think that you've made it. ... Wrong."
This Week in HIV Research: The Perils of Polypharmacy
Posted Feb 16, 3:34 p.m. ET
The risks of multiple non-HIV medication prescriptions; PrEP use and sexually transmitted infection incidence; how vaginal bacteria relate to HIV seroconversion; the effect of early treatment on HIV in the brain.
My Health Tracker can help you organize your HIV treatment information privately and securely in one place. This way, you can take better charge over your health, and you and your doctor can have even more productive conversations about your treatment.
Registration takes only a couple of minutes, requires no personal info, and you'll be able to pick up where you left off at any time.
Love Positive Women: Why a Fulfilling Sexual Life With HIV Matters
Allison Carter, Jessica Whitbread, and Angela Kaida, Canadian AIDS Treatment Information Exchange; Posted Feb 16, 1:09 p.m. ET
Although most attention is paid to preventing the transmission of HIV to intimate partners, women's sexual concerns go far beyond condom use.
U.S. Approve a Lower-Dose Efavirenz-Based Generic Fixed-Dose Combination (Symfi Lo)
Simon Collins, HIV i-Base; Posted Feb 15, 2:33 p.m. ET
On Feb. 7 2018, the U.S. FDA approved a new generic fixed-dose combination that uses a lower dose of Sustiva together with Epivir and Viread.
Homeless LGBTQ Youth Remain at Risk for HIV, and They Need Us
Giuliani Alvarenga, TheBody; Posted Feb 15, 1:16 p.m. ET
Homelessness is a problem in and of itself, but for LGBTQ youth, housing instability is also a significant risk factor for becoming HIV positive.
Bictegravir Approved in the U.S. in New Integrase Inhibitor-Based Fixed-Dose Combination (Biktarvy)
Simon Collins, HIV i-Base; Posted Feb 14, 9:58 p.m. ET
On Feb. 7, 2018, the U.S. FDA approved a new fixed-dose combination (FDC) containing bictegravir, emtricitabine and tenofovir alafenamide (TAF).
>> Browse Older Featured Stories